News and Trends 15 Jan 2018 British Biotech’s Technology is Taken by Pharma to Fight Alzheimer’s Having developed multispecific antibodies with F-star, Denali Therapeutics has joined forces with Takeda Pharmaceuticals to commercialize Alzheimer’s drugs using the technology. F-star’s bispecific antibody technology has received validation in the form of two pharma companies using it for the development of new drugs for neurodegenerative diseases. San Francisco-based Denali Therapeutics and Japanese company Takeda will collaborate on […] January 15, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 15 Jan 2018 The FDA Gives AstraZeneca’s Breast Cancer Drug the Go-Ahead The UK big pharma company’s Lynparza will be for women with advanced breast cancer that is specifically caused by mutations in the BRCA gene. Global pharma giant AstraZeneca focuses on the development of drugs for cancer, cardiovascular and respiratory diseases. The company, which is working on a number of small molecules and biologics for a […] January 15, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 12 Jan 2018 This Collaboration Will Develop a New Epilepsy Gene Therapy for In-Need Patients CombiGene and the Cell and Gene Therapy Catapult have struck a deal that will move the biotech’s epilepsy therapy towards the clinic. Swedish biotech CombiGene has combined neuroscience and advances in gene delivery to pioneer and new therapy for epilepsy that has brought down the number of seizures in preclinical studies. The company has joined forces […] January 12, 2018 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 12 Jan 2018 These Biomaterials Could Help to Make Stem Cell Therapies a Reality British researchers have developed biomaterials that better recreate the conditions required for stem cells to grow into desired cell types. Researchers at Imperial College London have used 3D printing to create biological structures that can support tissue regeneration. The study, published in Scientific Reports, outlines how the group used cryogenics – freezing – to create a biomaterial that mimics the […] January 12, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 11 Jan 2018 Here’s Another Reason to Eat Plenty of Fruit and Vegetables Researchers have discovered that bacteria break down fruit and vegetables to produce chemicals that control our genes and could help to prevent cancer and fight infections. British scientists from the Babraham Institute in Cambridge, UK, with colleagues from Brazil and Italy, have discovered a mechanism by which helpful bacteria in the gut can control the […] January 11, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 9 Jan 2018 Scancell and BioNTech Will Combine Their Expertise to Fight Cancer Scancell has brought in BioNTech to develop T-cell receptors against specific target proteins in cancer cells, opening the door to new cancer treatments that target them. Scancell works on immunotherapies for the treatment of cancer and it has announced that it will come together with Europe’s largest private biopharma, BioNTech, to develop T-cell receptor (TCR)-based therapies. […] January 9, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 9 Jan 2018 Adaptimmune Gets the Green Light for its New T-cell Cancer Therapy Following successful pilot studies, Adaptimmune will increase the dose of its T-cell therapy 10-fold to see if it remains safe, while also assessing its cancer-fighting capacity. Adaptimmune is a leader in the development of T-cell therapies for the treatment of cancer. It has been testing another one of its SPEAR T-cells in two pilot studies to determine […] January 9, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 8 Jan 2018 Biotech in London Paves the Way for a New Therapy for Ulcerative Colitis TopiVert has successfully completed a Phase I trial in ulcerative colitis with a new class of drug that could help reduce adverse side effects. The results of a Phase I trial run by London-based biotech TopiVert have shown potential for a new type of therapy for ulcerative colitis. The study revealed that the drug, called […] January 8, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 8 Jan 2018 This British Liquid Biopsy Could Save Us $5000 per Prostate Cancer Patient ANGLE’s liquid biopsy technology measures the expression of an important prostate cancer biomarker, helping to identify the best treatment for different groups of patients. ANGLE is a world leader in the development of liquid biopsies – a technique for the early detection of cancer, which doesn’t require invasive tissue samples. The biotech published results in […] January 8, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 8 Jan 2018 This Skin Patch Could Slow the Rate of Antibiotic Resistance Researchers have developed a skin patch that delivers drugs directly into the blood, avoiding the gut which is a breeding ground for antibiotic resistance. Researchers at Queen’s University Belfast are developing a skin patch to deliver drugs through the skin and directly into the bloodstream via thousands of ‘microneedles’. The technology is being tested as a […] January 8, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
Best in Biotech 26 Dec 2017 Interviews, Reviews and Tops: Our Best Biotech Articles from 2017 We love hearing from our readers, and we listen to what they like! Here are the long reads from our best biotech articles of 2017. We gave you a list of books to read this holiday season, but do you need something lighter for the post-Christmas daze? We’ve collected our most popular long articles of […] December 26, 2017 - 6 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
More News! 21 Dec 2017 Oxford Biotech Makes a Latin American Deal for Its Antibiotic In a deal worth up to €23.6M, Summit Therapeutics licensed the commercialization of its new antibiotic ridinilazole to Eurofarma. Oxford-based Summit Therapeutics is working on new antibiotics to fight antimicrobial resistance. Its candidate ridinilazole has attracted the attention of a Brazilian pharma, Eurofarma, and the pair has made a deal for $2.5M (€2.1M) upfront and […] December 21, 2017 - 1 minutemin - By Evelyn Warner Share WhatsApp Twitter Linkedin Email